Shin Poong Pharm.Co.,Ltd.

KSE 019170.KS

Shin Poong Pharm.Co.,Ltd. Receivables for the year ending December 31, 2023: USD 63.06 M

Shin Poong Pharm.Co.,Ltd. Receivables is USD 63.06 M for the year ending December 31, 2023, a -12.02% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Shin Poong Pharm.Co.,Ltd. Receivables for the year ending December 31, 2022 was USD 71.67 M, a -5.25% change year over year.
Shin Poong Pharm.Co.,Ltd. Receivables for the year ending December 31, 2021 was USD 75.64 M, a -9.47% change year over year.
Shin Poong Pharm.Co.,Ltd. Receivables for the year ending December 31, 2020 was USD 83.55 M, a -9.92% change year over year.
Shin Poong Pharm.Co.,Ltd. Receivables for the year ending December 31, 2019 was USD 92.75 M, a -7.05% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

KSE: 019170.KS

Shin Poong Pharm.Co.,Ltd.

CEO	Mr. Jei-Man Ryu
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	161, Yeoksam-ro
Employees	828
Sector	Healthcare
Industries Pharmaceuticals Automotive Parts Cleaning Supplies Composite Materials Drugstores & Retail Pharmacies Eyewear Personal Care Plastics

Description

Shin Poong Pharm.Co.,Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products. It also provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; and over the counter products. The company also exports its products to approximately 50 countries. Shin Poong Pharm.Co.,Ltd. was founded in 1962 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years